RESUMO
BACKGROUND: Rutin, often known as vitamin P, is a natural flavonoid compound, which offers a broad spectrum of therapeutic potentials. Rutin is metabolised to different compounds by the gut bacteria after consumption, therefore, very little is absorbed. Higher plants contribute to rutin synthesis in large quantities, and it may also be found in many fruits and fruity rinds, particularly citrus fruits and berries. OBJECTIVE: The present paper highlights several studies conducted on rutin along with its nanoformulations regarding its broad spectrum of therapeutic potentials. METHOD: Numerous electronic databases, including Springer, PubMed, Science Direct, Pubchem, etc. were searched to extract relevant published literature demonstrating rutin effectiveness in various ailments. RESULTS: The reviewed literature showed that rutin and related flavonoids possess a variety of physiological properties that protects human beings, plants and animals. Antioxidant, anti-inflammatory, anti-allergic, cytoprotective, vasoprotective, anticarcinogenic, neuroprotective, cardioprotective, antibacterial, antiviral, antiprotozoal, antitumor, anti-hypertensive antiplatelet, antispasmodic and hypolipidemic, activities. Nanotechnology has been implemented for the improvement of the bioavailability of rutin using novel drug-delivery carriers. CONCLUSION: The study concludes that the development of rutin nanoformulations for multiple therapeutic approaches contributes towards enhanced aqueous solubility as well as tailored pharmacokinetics compared to conventional delivery of rutin. However, more investigations should be conducted to confirm the improved bioavailability of the rutin nanoformulations.
RESUMO
BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease, progressively distinctive via cartilage destruction, auto-antibody production, severe joint pain, and synovial inflammation. Nanotechnology represents as one of the utmost promising scientific technologies of the 21st century. It exhibits remarkable potential in the field of medicine, including imaging techniques and diagnostic tools, drug delivery systems and providing advances in treatment of several diseases with nanosized structures (less than 100nm). OBJECTIVE: Conventional drugs as a cornerstone of RA management including disease-modifying antirheumatic drugs (DMARDS), Glucocorticosteroids, etc are under clinical practice. Nevertheless, their low solubility profile, poor pharmacokinetics behaviour, and non-targeted distribution not only hamper their effectiveness, but also give rise to severe adverse effects which leads to the need for the emergence of nanoscale drug delivery systems. METHODS: Several types of nano-diagnostic agents and nanocarriers have been identified; including polymeric nanoparticles (NPs), liposomes, nanogels, metallic NPs, nanofibres, carbon nanotubes, nano fullerene etc. Various patents and clinical trial data have been reported in relevance to RA treatment. RESULTS: Nanocarriers, unlike standard medications, encapsulate molecules with high drug loading efficacy and avoid drug leakage and burst release before reaching the inflamed sites. Because of its enhanced targeting specificity with the ability to solubilise hydrophobic drugs, it acts as an enhanced drug delivery system. CONCLUSION: This study explores nanoparticles potential role in RA as a carrier for site-specific delivery and its promising strategies to overcome the drawbacks. Hence, it concludes that nanomedicine is advantageous compared with conventional therapy to enhanced futuristic approach.